Considerations in the Design of Possible Cell Cycle Effective Drugs

References

• Adams E.G., Crampton S.L., Bhuyan B.K. Effect of 7-con-O-methylnogarol on DNA synthesis, survival, and cell cycle progression of Chinese hamster ovary cells. Cancer Research 1981; 41: 4981–4987
   PubMed Web of Science ®Google Scholar
• Baguley B.C., Denny W.A., Atwell G.J., Finlay G.J., Rewcastle G.W., Twigden S.J., Wilson W.R. Synthesis, antitumor activity, and DNA binding properties of a new derivative of Amsacrine, N-S-Dimethyl-9-(2-methoxy-4-methylsulfonylamino) phenylamino-4-acridinecarboxiamide. Cancer Research 1984; 44: 3245–3251
   PubMed Web of Science ®Google Scholar
• Barlogie B., Raber M.R., Schumann J., Johnson T.S., Drewinko B., Swartzendruber D.E., Göhde W., Andreeff M., Freireich E.J. Flow cytometry in clinical cancer research. Cancer Research 1983; 43: 3982–3997
   PubMed Web of Science ®Google Scholar
• Baserga R. Multiplication and Division in Mammalian Cells. Marcel Dekker, New York 1976
   Google Scholar
• Berembaum M.C. Dose-response curves for agents that impair cell reproductive integrity: A fundamental difference between dose-response curves for antimetabolites and those for radiation and alkylating agents. Antibiotics and Chemotherapy 1969; 15: 426–433
   Google Scholar
• Böhmer R.M. Flow cytometric cell cycle analysis using the quenching of 33258 Hoechst fluorescence by bromodeoxyuridine incorporation. Cell and Tissue Kinetics 1979; 12: 101–110
   PubMedGoogle Scholar
• Braunschweiger P.G., Ting H.L., Schiffer L.M. Receptor-mediated antiproliferative effects of corticosteroids in Lewis lung tumors. European Journal of Cancer and Clinical Oncology 1984; 20: 427–433
   Google Scholar
• Darzynkiewicz Z., Andreeff M., Tranganos F., Sharpless T., Melamed M.R. Discrimination of cycling and non-cycling lymphocytes by BudR-suppressed acridine orange fluorescence in a flow cytometric system. Experimental Cell Research 1978; 115: 31–35
   PubMed Web of Science ®Google Scholar
• Darzynkiewicz Z., Traganos F., Melamed M.R. New cell cycle compartments identified by multiparameter flow cytometry. Cytometry 1980; 1: 98–108
   PubMedGoogle Scholar
• Dethlefsen L.A. In quest of the quaint quiescent cells. Radiation Biology in Cancer Research, R.E. Meyn, H.R. Withers. Raven Press, New York 1980; 415–435
   Google Scholar
• DeVita V.T., Jr. Advances in cancer therapeutics: chemotherapy. Progress in Clinical and Biological Research 1983; 132: 47–69
   Google Scholar
• Dolbeare F., Gratzner H., Pallavicini M.G., Gray J.W. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proceedings of the National Academy of Sciences (U.S.A.) 1983; 80: 5573–5577
   PubMed Web of Science ®Google Scholar
• Drewinko B., Barlogie B. Cell cycle perturbation effects. Handbook of Experimental Pharmacology, B.W. Fox, M. Fox. Springer-Verlag, Heidelberg 1984; 101–141
   Google Scholar
• Drewinko B., Patchen H., Yang L.Y., Barlogie B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Research 1981; 41: 2328–2333
   PubMed Web of Science ®Google Scholar
• Drewinko B., Roper P.R., Barlogie B. Patterns of cell survival following treatment with antitumor agents in vitro. European Journal of Cancer 1979; 15: 93–99
   Google Scholar
• Drewinko B., Yang L.Y., Barlogie B. Lethal activity and kinetic response of cultured human cells to 4′-(9-acridinylamino) methanesulfon-m-anisidine. Cancer Research 1982; 42: 107–111
   Google Scholar
• Drewinko B., Yang L.Y., Barlogie B., Trujillo J.M. Cultured human tumour cells may be arrested in all stages of the cycle during stationary phase: demonstration of quiescent cells in G1, S and G2 phase. Cell and Tissue Kinetics 1984; 17: 453–463
   Google Scholar
• Durr F.E., Wallace R.E., Citarella R.V. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treatment Reviews 1983; 10(B)3–11
   PubMedGoogle Scholar
• Esnault C., Roques B.P., Jacquamir-Sablon A., Le Pecq J.B. Effects of new antitumor bifunctional intercalators derived from 7H-Pyridocarbazole on sensitive and resistant L1210 cells. Cancer Research 1984; 44: 4355–4360
   Google Scholar
• Franco P., Morelli S., Sarra F., Nicolin A. Inhibition of cellular DNA synthesis and lack of antileukemic activity by non-photoactivated hematoporphyrin derivative. Tumori 1981; 67: 183–189
   Google Scholar
• Freyer J.P., Sutherland R.M. Selective dissociation and characterization of cells from different regions of multicell tumor spheroids. Cancer Research 1980; 40: 3956–3965
   PubMed Web of Science ®Google Scholar
• Fujiwara T., Nakasone S., Matsumoto K., Ohmishi R., Tabuchi K., Nishimoto A. Effect of ACNU, a water-soluble nitrosurea, on cell cycle of cultured glioma cells: flow cytometric analysis. Gan To Kagaku Ryoho 1983; 10: 2055–2061
   Google Scholar
• Gelfant S. A new concept of tissue and tumor cell proliferation. Cancer Research 1977; 37: 3845–3862
   PubMed Web of Science ®Google Scholar
• Goldie J.H., Coldman J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Research 1984; 44: 3643–3653
   PubMed Web of Science ®Google Scholar
• Gratzner H. Monoclonal antibody to 5-Bromo and 5-Iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982; 218: 474–475
   PubMed Web of Science ®Google Scholar
• Hanna M.G., Jr., Key M.E., Oldham R.K. Biology of cancer therapy: some new insights into adjuvant treatment of metastatic solid tumors. Journal of Biological Response Modification 1983; 2: 295–309
   PubMedGoogle Scholar
• Heppner G.H., Miller B.E. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Reviews 1983; 2: 5–23
   PubMed Web of Science ®Google Scholar
• Hill B.T. Cancer chemotherapy: The relevance of certain concepts of the cell cycle kinetics. Biochimica et Biophysica Acta 1978; 516: 389–417
   PubMed Web of Science ®Google Scholar
• Howard A., Pelc S.R. Synthesis of desoxyribonucleic acid in normal and irradiated cells and its relation to chromosome damage. Heredity 1953; 6: 261–261, (Suppl.)
   Google Scholar
• Kanawaza H., Miyamoto T. Effect of ACNU, a water-soluble nitrosurea derivative, on survival and progression of cultured HeLa 53 cells. Gan To Kagaku Ryoho 1983; 10: 2007–2015
   Google Scholar
• Kato T., Takamoto S., Mizutami M., Hato M., Hota K. Anti tumor activities and mechanisms of action of harringtomine and homoharringtomine. Gan To Kagaku Ryoho 1984; 11: 2393–2399
   Google Scholar
• Kerbel R.S., Davies A.J. Facilitation of tumour progression by cancer therapy. Lancet 1982; 2: 977–987
   Google Scholar
• Kopf-Maier P., Wagner W., Liss E. Induction of cell arrest at G1/S and in G2 after treatment of Ehrlich ascites tumor cells with metallocene dichlorides and cis-platinum in vitro. Journal of Cancer Research and Clinical Oncology 1983; 106: 44–55
   PubMed Web of Science ®Google Scholar
• Langer E.M., Röttgers M.G., Schliermann M.G., Miltenburger H.G., Schumann J., Göhde W. Cycling S phase cells in animal and spontaneous tumors. I. Comparison of S phase frequencies estimated with the BudUrd techniques, using 3H thymidine and flow cytometry. Acta Radiologica 1985, in the press
   Google Scholar
• Latt S.A., George Y.S., Gray J.W. Flow cytometric analysis of bromodeoxyuridine-substituted cells stained with 33258 Hoechst. Journal of Histochemistry and Cytochemistry 1977; 25: 927–934
   PubMed Web of Science ®Google Scholar
• Lundblad D., Lundgren E. Block of glioma cell line in S by interferon. International Journal of Cancer 1981; 27: 749–754
   PubMedGoogle Scholar
• Madoc-Jones H., Mauro F. Site of action of cytotoxic agents in the cell life cycle, etc. Antineoplastic and Immunosuppressive Drugs, A. Sartorelli, D. Johns. Springer-Verlag, New York 1975; 205–219
   Google Scholar
• Mauro F., Briganti G., Nervi C. Antineoplastic drugs and radiation: comparison of the phenomena determining the effectiveness of fractionated treatments. Biological Bases and Clinical Implications of Tumor Radioresistance, G.H. Fletcher, C. Nervi, H.R. Withers, G. Arcangeli, F. Mauro, N. du V. Tapley. Masson Publishing USA, Inc., New York 1983 a; 33–42
   Google Scholar
• Mauro F., Spanò M., Teodori L., Drewinko B., Barlogie B. Cell cycle and effect of antineoplastic drugs: facts and pitfalls. Biology of Cancer, E.A. Mirand, W.B. Hutchinson, E. Mihich. Alan R. Liss, New York 1983 b; 199–209, (Part 2)
   Google Scholar
• Mirabelli C.K., Johnson R.K., Sung C.M., Faucette L., Muirhead K., Crooke S.T. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Research 1985; 45: 32–39
   PubMed Web of Science ®Google Scholar
• Nervi C., Badaracco G., Maisto A., Mauro F., Tirindelli-Danesi D., Starace G. Cytometric evidence of cytogenetic and proliferative heterogeneity of human solid tumors. Cytometry 1982; 2: 303–305
   Google Scholar
• Nowell P.C. The clonal evolution of tumor cell populations. Science 1976; 194: 23–28
   PubMed Web of Science ®Google Scholar
• Pettersen E.O., Ronning O.W., Nome O., Oftebro R. Effects of benzaldehyde on protein metabolism of human cells cultivated in vitro. European Journal of Cancer and Clinical Oncology 1983; 19: 935–940
   PubMedGoogle Scholar
• Poste G., Greig R. The experimental and clinical implications of cellular heterogeneity in malignant tumors. Journal of Cancer Research and Clinical Oncology 1983; 106: 159–170
   Google Scholar
• Sacchi A., Mauro F., Zupi G. Changes of phenotypic characteristics of variants derived from Lewis lung carcinoma during long-term in vitro growth. Clinical and Experimental Metastasis 1984; 2: 171–178
   Google Scholar
• Saimon S.E. Human tumor colony assay and chemosensitivity testing. Cancer Treatment Reports 1984; 68: 117–125
   Google Scholar
• Shiba D.A., Cosby L.A., Sartorelli A.C. Mechanism of action of arenesulfonylhydrazones of 2-pyridinecarboxeldehyde-1-oxide in L1210 cells. Cancer Research 1984; 44: 5707–5711
   PubMed Web of Science ®Google Scholar
• Shoemaker D.D., O'Dwyer P.J., Marsoni S., Plowman J., Davignon J.P., Davis R.D. Spiromustine: a new agent entering clinical trials. Investigational New Drugs 1983; 1: 303–308
   Google Scholar
• Sinclair W.K. Hydroxyruea: Differential lethal effects on cultured mammalian cells during the cell cycle. Science 1965; 150: 1729–1731
   Google Scholar
• Sinclair W.K. Hydroxyurea revisited: A decade of clinical effects studies. International Journal of Radiation, Oncology, Biology, Physics 1981; 7: 631–637
   Google Scholar
• Skipper H.E., Schabel F.M. Tumor stem cell heterogeneity: Implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treatment Reports 1984; 68: 43–61
   Google Scholar
• Slavik M., Blanc O., Davis J. Spirogermanium: A new investigational drug of novel structure and lack of bone marrow toxicity. Investigational New Drugs 1983; 1: 225–234
   Google Scholar
• Steel G.G. The Growth Kinetics of Tumors. Oxford University Press, Oxford 1977
   Google Scholar
• Swartzendruber D.E. A bromodeoxyuridine (BUdR)-mithramycin technique for detecting cycling and non-cycling cells by flow microfluorometry. Experimental Cell Research 1977; 109: 439–443
   PubMed Web of Science ®Google Scholar
• Tannock I. Cell kinetics and chemotherapy: A critical review. Cancer Treatment Reports 1978; 62: 1117–1133
   PubMedGoogle Scholar
• Teichner B.A., Lazo J.S., Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Research 1981; 41: 73–81
   Google Scholar
• Teodori L., Tirindelli-Danesi D., Mauro F., De Vita R., Uccelli R., Botti C., Modini C., Nervi C., Stipa S. Non-small-cell lung carcinoma: tumor characterization on the basis of flow cytometrically determined cellular heterogeneity. Cytometry 1983; 4: 174–183
   PubMedGoogle Scholar
• Terasima T., Takabe Y., Katsumata T., Watanabe M., Umezawa H. Effect of Bleomycin on mammalian cell survival. Journal of the National Cancer Institute 1972; 49: 1093–1100
   PubMedGoogle Scholar
• Terasima T., Tolmach L.J. Changes in X-rays sensitivity of HeLa cells during the division cycle. Nature 1961; 190: 1210–1211
   PubMed Web of Science ®Google Scholar
• Thornthwaite E.V., Sugarbaker E.V., Temple W.J. Preparation of tissues for DNA flow cytometric analysis. Cytometry 1980; 1: 229–237
   PubMedGoogle Scholar
• Traganos F., Darzynkiewicz Z., Bueti C., Melamed M.R. Effects of a prospective antitumor agent, 1,4-bis(2′-chloroethyl)-1,4-diazabicyclo- 2.21 heptane diperchlorate, on cultured mammalian cells. Cancer Investigation 1984; 2: 1–13
   PubMed Web of Science ®Google Scholar
• Tsou K.C., Xu B., Miller E.E., Lo K.W. Anti-tumor effect of (S)-10-hydroxycamptothecin on mouse hepatoma BW7756 and its possible mode of action. Anticancer Research 1981; 1: 115–119
   Google Scholar
• Tsuruo T., Fidler I.J. Difference in drug sensitivity among tumor cells from parental tumors, selected variants, and spontaneous metastases. Cancer Research 1981; 41: 3058–3064
   PubMed Web of Science ®Google Scholar
• Tubiana M., Frindel E., Vassort F. Critical survey of experimental data on in vivo synchronization by hydroxyurea. Recent Reports in Cancer Research 1975; 52: 187–205
   Google Scholar
• Wakabashi R., Yoshida J., Inoue I., Kagayama N., Nagata M., Kenzeki M. MCNU effectiveness on brain tumor. Part I: Antitumor activity in vivo on human glioma and neuroblastoma cell lines. Gan To Kagaku Ryoho 1984; 11: 1098–1106
   Google Scholar
• Xu B. The influence of several anticancer agents on cell proliferation, differentiation and the cell cycle of murine erythroleukemia cells. American Journal of Clinical Medicine 1981; 9: 268–276
   Google Scholar
• Yung W.K., Shapiro J.R., Shapiro W.R. Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Research 1982; 42: 992–998
   PubMed Web of Science ®Google Scholar